CD64 has been shown to be a good choice of target for the development of therapies against many kinds of monocyte/macrophages related inflammatory diseases such as rheumatoid arthritis, inflammatory skin diseases and acute myeloid leukemia (AML). The gene discussed is FCGR1A; the disease is rheumatoid arthritis.